Fred Hutchinson Cancer Center 10916408

1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis

NIH-funded clinical trial to evaluate ganciclovir for preventing CMV reactivation in sepsis patients with respiratory failure, assessing clinical outcomes in a phase 3 trial.

Description

This is a NIH-funded clinical trial project focusing on the use of ganciclovir to prevent CMV reactivation in patients with sepsis-associated respiratory failure. The project involves multiple investigators and a network of clinical sites. The project aims to conduct a phase 3 randomized controlled trial to evaluate clinical outcomes such as ventilator-free days, mortality, and long-term health outcomes.

View original record